| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the University of Manitoba, Winnipeg
2 From the University of Alabama at Birmingham
3 From the University of Minnesota, Minneapolis
4 From the Oregon Health Sciences University, Portland
5 From the University of California, Los Angeles
6 From the National Heart, Lung, and Blood Institute, Bethesda, Md
Study objective: To assess cardiovascular conditions and other side effects associated with the use of nicotine polacrilex (NP), 2 mg.
Design: A multicentered randomized control trial of early intervention for the prevention of COPD.
Setting: Ten university medical centers in the United States and Canada.
Participants: Adult smoking volunteers with evidence of early COPD; 3,923 in intervention and 1,964 controls.
Intervention: Smoking cessation program, including NP.
Measurements: Data on hospitalizations were collected annually. Data on reported NP side effects were collected at 4-month intervals for intervention participants.
Results: The rates of hospitalization for cardiovascular conditions and cardiovascular deaths during the 5 years of the studywere not related to use of NP, to dose of NP, or to concomitant use of NP and cigarettes. About 25% of NP users reported at least one side effect, but most were very minor and transient. Side effects associated with discontinuance of NP in 5% or more of users included headache, indigestion, mouth irritation, mouth ulcers, and nausea. There was no evidence that concomitant use of NP and cigarettes was associated with elevated rates of reported side effects. Participants in the smoking cessation intervention who received intensive levels of instruction tand monitoring of NP use (initially at 12 meetings during 3 months) appeared to report significantly lower rates of side effects (dizziness, headache, and throat irritation) than control participants, presumed to have less instruction and monitoring.
Conclusions: NP, as used in the Lung Health Study, appears to be safe and unrelated to any cardiovascular illnesses or other serious side effects.
Key Words: cardiovascular illness • clinical trial • nicotine gum • side effects • smoking cessation
Submitted on April 18, 1995
Accepted on September 7, 2007
This article has been cited by other articles:
|
|
 |
|
  M. B. Steinberg, A. C. Schmelzer, D. L. Richardson, and J. Foulds The Case for Treating Tobacco Dependence as a Chronic Disease Ann Intern Med, April 1, 2008; 148(7): 554 - 556. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M Decramer, R Gosselink, P Bartsch, C-G Lofdahl, W Vincken, R Dekhuijzen, J Vestbo, R Pauwels, R Naeije, and T Troosters Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004 Thorax, April 1, 2005; 60(4): 343 - 349. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. P. Winickoff, S. E. Tanski, R. C. McMillen, J. D. Klein, N. A. Rigotti, and M. Weitzman Child Health Care Clinicians' Use of Medications to Help Parents Quit Smoking: A National Parent Survey Pediatrics, April 1, 2005; 115(4): 1013 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Winickoff, A. B. Berkowitz, K. Brooks, S. E. Tanski, A. Geller, C. Thomson, H. A. Lando, S. Curry, M. Muramoto, A. V. Prokhorov, et al. State-of-the-Art Interventions for Office-Based Parental Tobacco Control Pediatrics, March 1, 2005; 115(3): 750 - 760. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. M. Hall, G. L. Humfleet, V. I. Reus, R. F. Munoz, and J. Cullen Extended Nortriptyline and Psychological Treatment for Cigarette Smoking Am J Psychiatry, November 1, 2004; 161(11): 2100 - 2107. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Gupta, H. Gurm, and J. R. Bartholomew Smokeless Tobacco and Cardiovascular Risk Arch Intern Med, September 27, 2004; 164(17): 1845 - 1849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. R. Lingford-Hughes, S. Welch, and D. J. Nutt Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology J Psychopharmacol, September 1, 2004; 18(3): 293 - 335. [PDF]
|
|
|
|
 |
|
 S Shiffman, J R Hughes, J L Pillitteri, and S L Burton Persistent use of nicotine replacement therapy: an analysis of actual purchase patterns in a population based sample Tob. Control, September 1, 2003; 12(3): 310 - 316. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W Sumner II Estimating the health consequences of replacing cigarettes with nicotine inhalers Tob. Control, June 1, 2003; 12(2): 124 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 STUDY SUGGESTS NICOTINE MAY PROMOTE CANCER DEVELOPMENT CA Cancer J Clin, March 1, 2003; 53(2): 66 - 67. [Full Text] [PDF]
|
|
|
|
|
|
S. Shiffman, C. M. Dresler, P. Hajek, S. J. A. Gilburt, D. A. Targett, and K. R. Strahs Efficacy of a Nicotine Lozenge for Smoking Cessation Arch Intern Med, June 10, 2002; 162(11): 1267 - 1276. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. T KOZLOWSKI, A. A STRASSER, G. A GIOVINO, P. A ERICKSON, and J. V TERZA Applying the risk/use equilibrium: use medicinal nicotine now for harm reduction Tob. Control, September 1, 2001; 10(3): 201 - 203. [Full Text] [PDF]
|
|
|
|
 |
|
 C. T Bolliger, J.-P. Zellweger, T. Danielsson, X. van Biljon, A. Robidou, A. Westin, A. P Perruchoud, and U. Säwe Smoking reduction with oral nicotine inhalers: double blind, randomised clinical trial of efficacy and safety BMJ, August 5, 2000; 321(7257): 329 - 333. [Abstract] [Full Text]
|
|
|
|
 |
|
 J. R. Hughes, M. G. Goldstein, R. D. Hurt, and S. Shiffman Recent Advances in the Pharmacotherapy of Smoking JAMA, January 6, 1999; 281(1): 72 - 76. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
